C/V ENT Surgical Group C/V ENT Surgical Group C/V ENT Surgical Group C/V ENT Surgical Group C/V ENT Surgical Group C/V ENT Surgical Group

ZERONA LASER ARRIVES AT C/V!

October 25th, 2009

C/V ENT Surgical Group announces the arrival of the ZERONA®, the only non-invasive, body slimming, low-level laser treatment, to their practice, making them one of the first and only physicians to offer the ZERONA™ in the West San Fernando Valley area.  During clinical trials, the ZERONA® has been scientifically proven to result in an average of 3.6 inches lost from patients’ waist, hips and thighs. Unlike invasive weight loss surgery, ZERONA® is a revolutionary method that is applied externally without the dangers associated with surgery or other non-invasive devices which rely on heating the tissue.  The new technology has been proven to reduce inches from target areas such as the tummy, back, hips, thighs, buttocks, chin, neck and arms; contour and reshape the body; and tighten and tone loose skin.

The introduction of ZERONA® to C/V ENT Surgical Group will provide those seeking a safe alternative to surgery with a body contouring program that causes no bruising, scarring and discomfort.   The simple procedure consists of six 40-minute treatments over a two-week period. 

 Dr. Cohen says, “Our patients have been pleased with the results from ZERONA® treatments and because there are no needles, no incisions and no recovery time involved, they can continue with their daily activities immediately after each treatment.  ZERONA® is an excellent option for patients who do not want to experience the downtime, health risks or pain associated with more invasive procedures for body countouring.”

Clinical studies demonstrated that the ZERONA® low-level laser targets adipose tissue (fat storing cells) and stimulates the fat cell to liquefy the fat within the cell.  The excess fat is then passed out of the body during its normal course of detoxification which results in millions of fat cells becoming smaller and inches are reduced.

For more information on the ZERONA® treatments or to book a free consultation at C/V ENT Surgical Group, visit www.zerona.com or call (818)888-7878.

THYROID CANCER AWARENESS

July 12th, 2009

Thyroid Cancer Awareness is an important cause as I have dedicated my career to the surgical treatment of patients with thyroid cancer. The American Cancer Society reports that in 2009 there will be 37,200 new cases of thyroid cancer (27,200 in women, and 10,000 in men) with an estimated 1,630 deaths. That’s up from 33,550 in 2007, making it a 10% increase in just 2 years. Thyroid cancer is, however, considered one of the least deadly and most survivable cancers, and 5-year survival rates for most thyroid cancers is around 97%. The reason for this excellent rate of survival is primarily due to having thyroid surgery by expert thyroid surgeons including myself.

Thyroid cancer is one of the few cancers on the rise in recent years, with a growth rate of about 6% a year since 1997. Most experts and I believe that this increase is primarily due to a greater use of advanced imaging techniques such as CT, MRI and ultrasound, which often will identify asymptomatic thyroid nodules earlier which after further workup are deemed to be cancerous and treated accordingly.

As such September is designated as Thyroid Cancer Awareness month and to commemorate the month I will lead various discussions and community programs to educate the public throughout the month. I also recommend patients to consider an annual self exam or “thyroid check” by standing in front of the mirror and feeling for any lumps or bumps along the central lower neck that present with swallowing. If anything abnormal is felt, then you should consult your doctor for a full and complete examination.

Alen N. Cohen, M.D., F.A.C.S.

Here is a listing of our publications to date.

January 22nd, 2009

Publications by Dr. Cohen:

  1. Cohen A. Fen-phen and Valvular Heart Disease. Nutrition Bytes. 1998; 4(3). http://www.medsch.ucla.edu/som/ddo/biolchem/nut-1998/ByteV4N3/v4n3cohe.html Click Here
  2. Paiva MB, Saxton RE, Blackwell K, Buecher P, Cohen A, Calcaterra TC, Ward PH, Castro DJ. Combined Cisplatinum and Laser Thermal Therapy for Palliation of Recurrent Head and Neck Tumors. Diagnostic and Therapeutic Endoscopy. 2000; 6: 133-140. Click Here
  3. Huang RY, Damrose EJ, Blackwell KE, Cohen AN, Calcaterra TC.
      i. Extranasopharyngeal Angiofibromas. International Journal of Pediatric
      ii. Otorhinolaryngology. 2000; 54(1): 1-5. Click Here
  4. Cohen AN, Damrose EJ, Huang RY, Nelson SD, Blackwell KE, Calcaterra TC. Adenoid Cystic Carcinoma of the Submandibular Gland: A 35 Year Review. Otolarygol Head Neck Surg. 2004;131(6):994-1000. Click Here
  5. Maria M. LoTempio, Mysore S. Veena, Helen L. Steele, Bharathi Ramamurthy, Tirunelveli S. Ramalingam, Alen N. Cohen, Rita Chakrabarti, Eri S. Srivatsan, Marilene B. Wang. Curcumin Suppresses Growth Of Head And Neck Squamous Cell Carcinoma. Clinical Cancer Research. 2005;11(19):6994-7002. Click Here
  6. Cohen AN, Wang MB. Mini-Trephination as an Adjunctive Measure in the Endoscopic Management of Complex Frontal Sinus Disease. American J of Rhinology. 2007;21:629-636. Click Here
  7. Strocker AM, Cohen AN, Wang MB. The Safety of Outpatient UPPP for Obstructive Sleep Apnea: A Retrospective Review of 40 Cases. Ear Nose Throat J. 2008;87(8):466-468. Click Here
  8. Cohen AN, Veena MS, Srivatsan ES, Wang MB. Suppression of Interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition Ikappa beta kinase. Arch Otolaryngol Head Neck Surg. 2009;135(2):190-197. Click Here

SDF Publications by Dr. Vener:

  1. Vener J, Zuckerbraun L. Carotid Body Tumors – A Report of 4 Cases and Their Surgical Management.
  2. Vener J, Zuckerbraun L. Thymic Carinoid Tumors in Assoication with a Parathyroid Adenoma. Arch Otolaryngol Head Neck Surg. 1982. Click Here
  3. Vener J, Rice D, Newman A. Osteosarcoma of the Head and Neck. Laryngoscope. 1984(94). Click Here